AstraZeneca Elevates Shanghai to Its Fifth Global Strategic Center

According to AstraZeneca China, the "2024 Shanghai Biomedical Industry International Development Conference" was held today. Leveraging the conference as an opportunity, AstraZeneca further deepened its strategic layout in China by announcing that Shanghai will become its fifth global strategic center. It also launched the "2024 Shanghai Pharmaceutical Innovation Enterprise Collaboration Overseas Expansion Plan." During the conference, AstraZeneca, in collaboration with Zhongshan Hospital of Fudan University, announced the launch of the "Green Ribbon Liver Cancer Early Screening and Diagnosis Initiative" to help establish an early liver cancer screening "Shanghai Model" and build a modern healthcare ecosystem template. (Securities Times)Original Link